Literature DB >> 35689092

Plasma and serum prorenin concentrations in diabetes, hypertension, and renal disease.

Sayuki Kawamura1, Kazumi Fujimoto1, Akinori Hayashi1, Yuji Kamata1, Ibuki Moriguchi2, Naoyuki Kobayashi2, Masayoshi Shichiri3,4.   

Abstract

Although the renin-angiotensin-aldosterone system plays a crucial role in fluid homeostasis and cardiovascular disease pathophysiology, measurements of plasma prorenin levels are still unavailable in clinical practice. We previously found that prorenin molecules in human blood underwent significant posttranslational modifications and were undetectable using immunological assays that utilized antibodies specifically recognizing unmodified recombinant prorenin. Using a sandwich enzyme-linked immunosorbent assay that captures posttranslationally modified prorenins with their prosegment antibodies, we measured plasma and serum prorenin concentrations in 219 patients with diabetes mellitus, hypertension and/or renal disease and compared them with those of 40 healthy controls. The measured values were not significantly different from those of the healthy controls and were 1,000- to 100,000-fold higher than previously reported levels determined using conventional assay kits. Multiple regression analyses showed that body weight, serum albumin levels, and serum creatinine levels negatively correlated with plasma prorenin levels, while the use of loop diuretics was associated with elevated plasma prorenin levels. Blood pressure, HbA1c, and plasma renin activity were not independent variables affecting plasma prorenin levels. In contrast, serum prorenin levels were unaffected by any of the above clinical parameters. The association of the plasma prorenin concentration with indices reflecting body fluid status suggests the need to scrutinize its role as a biomarker, while serum prorenins are less likely to have immediate diagnostic value.
© 2022. The Author(s), under exclusive licence to The Japanese Society of Hypertension.

Entities:  

Keywords:  Diabetes; Enzyme-linked immunosorbent assay; Plasma prorenin; Renal disease; Serum prorenin

Year:  2022        PMID: 35689092     DOI: 10.1038/s41440-022-00959-4

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   5.528


  38 in total

1.  Plasma renin activity and plasma aldosterone during the normal menstrual cycle.

Authors:  A M Michelakis; H Yoshida; J C Dormois
Journal:  Am J Obstet Gynecol       Date:  1975-12-01       Impact factor: 8.661

Review 2.  Primary aldosteronism.

Authors:  R D Gordon
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

Review 3.  Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease.

Authors:  J H Laragh; L Baer; H R Brunner; F R Buhler; J E Sealey; E D Vaughan
Journal:  Am J Med       Date:  1972-05       Impact factor: 4.965

4.  A diurnal rhythm in plasma renin activity in man.

Authors:  R D Gordon; L K Wolfe; D P Island; G W Liddle
Journal:  J Clin Invest       Date:  1966-10       Impact factor: 14.808

5.  Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity.

Authors:  F H Derkx; R J de Bruin; J M van Gool; M J van den Hoek; C C Beerendonk; F Rosmalen; P Haima; M A Schalekamp
Journal:  Clin Chem       Date:  1996-07       Impact factor: 8.327

6.  Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men?

Authors:  Ashraf H Ahmed; Richard D Gordon; Paul J Taylor; Gregory Ward; Eduardo Pimenta; Michael Stowasser
Journal:  J Clin Endocrinol Metab       Date:  2010-10-20       Impact factor: 5.958

7.  The effect of posture and saline loading on plasma renin activity and aldosterone concentration in pregnant, non-pregnant and estrogen-treated women.

Authors:  M H Weinberger; N J Kramer; C E Grim; L P Petersen
Journal:  J Clin Endocrinol Metab       Date:  1977-01       Impact factor: 5.958

Review 8.  Activity assays and immunoassays for plasma Renin and prorenin: information provided and precautions necessary for accurate measurement.

Authors:  Duncan J Campbell; Juerg Nussberger; Michael Stowasser; A H Jan Danser; Alberto Morganti; Erik Frandsen; Joël Ménard
Journal:  Clin Chem       Date:  2009-03-05       Impact factor: 8.327

9.  Characterization of angiotensin peptides in plasma of anephric man.

Authors:  D J Campbell; A Kladis; S L Skinner; J A Whitworth
Journal:  J Hypertens       Date:  1991-03       Impact factor: 4.844

10.  Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline.

Authors:  John W Funder; Robert M Carey; Carlos Fardella; Celso E Gomez-Sanchez; Franco Mantero; Michael Stowasser; William F Young; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-06-13       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.